Pharmaceutical Business Intelligence

  • Find generic sources and suppliers
  • Uncover prior art in abandoned patent applications and expired patents
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview


« Back to Dashboard

Which patents cover Octreotide Acetate, and what substitute generic drugs are available?

Octreotide Acetate is a drug marketed by Sun Pharm Inds, West-ward Pharms Int, Sagent Pharms, Fresenius Kabi Usa, Teva Pharms Usa, Wockhardt Usa, and Mylan Institutional. and is included in sixteen NDAs.

The generic ingredient in OCTREOTIDE ACETATE is octreotide acetate. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the octreotide acetate profile page.

Summary for Tradename: OCTREOTIDE ACETATE

Suppliers / Packagers: see list5
Bulk Api Vendors: see list70
Clinical Trials: see list515
Patent Applications: see list5,950
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OCTREOTIDE ACETATE at DailyMed

Pharmacology for Tradename: OCTREOTIDE ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa
octreotide acetate
INJECTABLE;INJECTION077457-003Feb 10, 2006RXNoNo► Subscribe► Subscribe
Sagent Pharms
octreotide acetate
INJECTABLE;INJECTION090834-002Nov 12, 2013RXNoNo► Subscribe► Subscribe
Mylan Institutional
octreotide acetate
INJECTABLE;INJECTION079198-001Feb 10, 2011RXNoNo► Subscribe► Subscribe
Sagent Pharms
octreotide acetate
INJECTABLE;INJECTION090834-003Nov 12, 2013RXNoNo► Subscribe► Subscribe
Sun Pharm Inds
octreotide acetate
INJECTABLE;INJECTION077329-001Mar 4, 2008RXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: OCTREOTIDE ACETATE

Drugname Dosage Strength RLD Submissiondate
octreotide acetateInjection0.05 mg/mL (base), 0.1 mg/mL (base) and 0.5 mg/mL (base) packaged in 1 mL pre-fiOctreotide Acetate I1/17/2008
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.